Buy 5-MeO-DALT for sale online from USA vendor
Table of Contents
- Introduction
- Chemistry
- Pharmacology
- Dosage Recommendations
- Physical Effects
- Visual Effects
- Cognitive Effects
- Toxicity and Harm Potential
- Tolerance and Addiction Potential
- Dangerous Interactions
- Legal Status
Origins and Synthesis
N,N-Diallyl-5-methoxytryptamine, commonly referred to as 5-MeO-DALT or colloquially known as Foxtrot, belongs to the lesser-known psychedelic substances within the tryptamine class. Initially synthesized by Alexander Shulgin, the first material regarding its synthesis and effects was shared with a researcher in May 2004. This information soon circulated online, leading to its appearance on the online research chemical market. In August 2004, Erowid officially published the synthesis and effects of 5-MeO-DALT. Reports of its detection began emerging in 2007.
Unique Effects and Characteristics
Anecdotal reports provide insights into the effects of 5-MeO-DALT, which are primarily physical in nature, distinguishing it from other tryptamines like 5-MeO-DiPT and DALT. Unlike many psychedelics, it lacks the characteristic visual distortions or profound perceptual depth. Descriptions of its headspace often depict it as "shallow," though particularly suitable for sexual contexts due to its potent stimulating and libidinous effects. However, it's noted for inducing uncomfortable cardiovascular effects such as increased blood pressure and heart rate, raising concerns about potential toxicity associated with long-term or heavy use.
Pharmacological Properties and Safety Considerations
Despite its presence in the research chemical market, very limited data exists regarding the pharmacological properties, metabolism, and toxicity of 5-MeO-DALT. Moreover, its history of human use is relatively short. Due to this lack of comprehensive understanding, it is strongly advised to employ harm reduction practices when considering the use of this substance.
Unveiling the Chemistry of 5-MeO-DALT
Chemical Structure and Related Compounds
N,N-Diallyl-5-methoxytryptamine, commonly known as 5-MeO-DALT, is structurally related to 5-MeO-DPT and DALT (N,N-Diallyltryptamine). Its full chemical name is N-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl] prop-2-en-1-amine. The nomenclature "5-MeO-DALT" stems from its chemical composition, signifying 5-MethOxy-DiALlylTryptamine. This compound features two allyl groups bound to the amino group and a 5-methoxy group attached to the indole ring of tryptamine. It serves as a structural analog of DALT and 5-MeO-DiPT, presenting as an off-white powder at room temperature.
Pharmacological Insights
5-MeO-DALT exhibits binding affinities to various serotonin receptors, including 5-HT1A, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT6, as well as to α2A, α2B, and α2C adrenergic receptors, H1 histamine receptors, κ-opioid receptors, and σ1 and σ2 receptors, with Ki values lower than 10μM. Additionally, it acts as a monoamine reuptake inhibitor of the dopamine transporter (DAT) and serotonin transporter (SERT).
The psychedelic effects of 5-MeO-DALT are primarily attributed to its partial agonist activity at the 5-HT2A receptors. However, the precise mechanisms underlying these interactions and how they contribute to the psychedelic experience remain subjects of ongoing scientific investigation. Notably, 5-MeO-DALT has been employed as an intermediate in the synthesis of radiolabeled diethyltryptamine.
Subjective Effects
Disclaimer: The following effects are derived from anecdotal user reports and the analyses of contributors to the Subjective Effect Index (SEI). As such, they should be interpreted with a degree of caution. It is essential to recognize that individual experiences may vary, and higher doses can increase the likelihood of both positive and adverse effects, including addiction, severe injury, or fatality.
Chemical Composition and Structure
The chemical compound N,N-Diallyl-5-methoxytryptamine, commonly known as 5-MeO-DALT or Foxtrot, boasts a full chemical name of N-allyl-N-[2-(5-methoxy-1H-indol-3-yl)ethyl] prop-2-en-1-amine. It shares structural similarities with 5-MeO-DPT and DALT (N,N-Diallyltryptamine). Named for its chemical structure, 5-MeO-DALT contains two allyl groups attached to the amino group and a 5-methoxy group bound to the indole ring of tryptamine. It is considered a structural analog of DALT and 5-MeO-DiPT, presenting as an off-white powder at room temperature.
Pharmacological Profile
5-MeO-DALT interacts with various serotonin receptors, including 5-HT1A, 5-HT1D, 5-HT1E, 5-HT2A, 5-HT2B, 5-HT2C, and 5-HT6, alongside α2A, α2B, and α2C adrenergic receptors, histamine H1 receptors, κ-opioid receptors, and sigma receptors σ1 and σ2. It exhibits Ki values lower than 10μM and also serves as a monoamine reuptake inhibitor for dopamine transporter (DAT) and serotonin transporter (SERT).
Acting as a partial agonist at the 5-HT2A receptor, 5-MeO-DALT's psychedelic effects are believed to stem from its interaction with this receptor subtype. However, the precise mechanisms underlying these interactions and their contribution to the psychedelic experience remain subjects of ongoing scientific inquiry. Additionally, 5-MeO-DALT has been utilized as an intermediate in the preparation of radiolabeled diethyltryptamine.
Dosage Recommendations
- Threshold: 4 mg
- Light: 5 - 12 mg
- Common: 12 - 25 mg
- Strong: 25 - 35 mg
- Heavy: 35 mg and above
It's crucial to approach dosing with caution, as individual responses may vary significantly. Adherence to proper dosage guidelines is essential to mitigate risks and ensure a safe and enjoyable experience.
Physical Effects
Stimulation
-
Spontaneous Physical Sensations: The "body high" induced by 5-MeO-DALT manifests as a motionless, constant, sharp, and all-encompassing tingling sensation. This sensation steadily intensifies throughout the come-up phase, reaching its peak during the zenith of the experience.
-
Tactile Enhancement
-
Increased Heart Rate [citation needed]
-
Increased Blood Pressure [citation needed]
-
Suppression of Temperature Regulation
-
Pupil Dilation
Visual Effects
- Enhancements
- Acuity Enhancement
- Colour Enhancement
- Pattern Recognition Enhancement
- Distortions
- Drifting (Melting, Flowing, Breathing, and Morphing): Compared to other psychedelics, this effect is characterized by simplicity, slow and smooth motion, static appearance, and unrealistic style.
- Colour Shifting
- Symmetrical Texture Repetition
- Tracers
- Geometry: The visual geometry resembles that of AMT more than LSD, 2C-B, or 2C-I. It is described as unstructured, synthetic in style, intricate, small in size, slow and smooth in motion, colorful, glossy in color, and equally blurred and sharp in edges and corners. It possesses a synthetic feel that is less pronounced than most "classical" psychedelics at any level. It remains uncertain whether this compound induces level 8A or level 8B geometry at heavy doses.
Cognitive Effects
- The headspace induced by 5-MeO-DALT is often described as insightful and relatively normal in thought processes even at moderate to high doses.
- Analysis Enhancement
- Conceptual Thinking
- Emotion Enhancement
- Increased Libido
- Increased Music Appreciation
- Memory Suppression
- Novelty Enhancement
- Personal Bias Suppression
- Thought Acceleration
- Thought Connectivity
- Time Distortion
- Wakefulness
Auditory Effects
- Enhancements
- Distortions
- Hallucinations
It's important to note that the effects listed above are based on anecdotal user reports and should be approached with caution, as individual experiences may vary. Additionally, higher doses may increase the likelihood of adverse effects and should be approached with appropriate caution and preparation.
Toxicity and Harm Potential
Lack of Scientific Study
The toxicity and long-term health effects of recreational 5-MeO-DALT usage have not been studied extensively in scientific contexts, and the precise toxic dose remains unknown. This scarcity of data stems from 5-MeO-DALT's classification as a research chemical, with minimal history of human consumption.
Anecdotal Reports and Cautionary Measures
Reports from individuals who have experimented with 5-MeO-DALT suggest no notable negative health effects when used alone at low to moderate doses and with minimal frequency. However, it's essential to exercise caution, as individual reactions may vary. Independent research is advised to assess the safety of combining 5-MeO-DALT with other substances.
Harm Reduction Practices
It is strongly recommended to incorporate harm reduction strategies when using this substance. This includes thorough research, careful dosing, and creating a safe and supportive environment for consumption.
Tolerance and Addiction Potential
5-MeO-DALT is not considered habit-forming, and the desire to use it may decrease with continued usage. Tolerance to its effects builds rapidly after ingestion, typically requiring around three days for tolerance levels to decrease by half and approximately seven days to return to baseline in the absence of further consumption. Additionally, 5-MeO-DALT induces cross-tolerance with other psychedelics, diminishing their effects.
Dangerous Interactions
Combining 5-MeO-DALT with certain substances can pose significant risks, potentially leading to adverse effects or life-threatening situations. It is crucial to conduct thorough research to ensure the safety of combining multiple substances. Some known dangerous interactions include:
- 2C-T-X
- 2C-X
- Cannabis
- DOx
- MDMA
- Mescaline
- NBOMe
- Amphetamines
- Cocaine
- DXM
- Tramadol
- aMT
- MAOIs
- PCP
Legal Status
The legal status of 5-MeO-DALT varies by country:
- Austria: Illegal
- China: Controlled substance
- Germany: Controlled substance
- Japan: Controlled substance
- Sweden: Schedule I substance
- Slovakia: Schedule I substance
- Switzerland: Controlled substance
- United Kingdom: Class A drug
- United States: Unscheduled, but potentially prosecutable under analogue laws
- Florida: Schedule I controlled substance
Frequently Asked Questions (FAQ)
1. What is 5-MeO-DALT?
5-MeO-DALT, also known as N,N-Diallyl-5-methoxytryptamine or colloquially as Foxtrot, is a lesser-known psychedelic substance belonging to the tryptamine class. It was first synthesized by Alexander Shulgin and gained popularity in online research chemical markets.
2. How does 5-MeO-DALT affect the body?
5-MeO-DALT interacts with various serotonin receptors, dopamine transporter (DAT), and serotonin transporter (SERT). It is primarily a partial agonist at the 5-HT2A receptor, leading to psychedelic effects. These effects can include stimulation, tactile enhancement, increased heart rate and blood pressure, pupil dilation, visual enhancements and distortions, cognitive alterations, and auditory enhancements and distortions.
3. What are the recommended dosages for 5-MeO-DALT?
The recommended dosages for 5-MeO-DALT vary depending on the desired effects:
- Threshold: 4 mg
- Light: 5 - 12 mg
- Common: 12 - 25 mg
- Strong: 25 - 35 mg
- Heavy: 35 mg and above
4. Is 5-MeO-DALT addictive?
5-MeO-DALT is not considered habit-forming, and the desire to use it may decrease with continued usage. However, tolerance to its effects can develop rapidly, and cross-tolerance with other psychedelics may occur.
5. What precautions should be taken when using 5-MeO-DALT?
It is strongly recommended to practice harm reduction techniques, including thorough research, careful dosing, and creating a safe and supportive environment for consumption. Additionally, caution should be exercised when combining 5-MeO-DALT with other substances, as dangerous interactions may occur.
6. What is the legal status of 5-MeO-DALT?
The legal status of 5-MeO-DALT varies by country, with some countries banning its possession, production, and sale, while others have not yet regulated it. It is essential to check the specific laws and regulations in your jurisdiction before acquiring or using 5-MeO-DALT.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics